61 citations
,
January 2015 in “Hormones” Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.
1 citations
,
September 2025 in “Medicina Moderna - Modern Medicine” Combining lifestyle changes with personalized medication is crucial for better managing obesity in PCOS.
May 2026 in “Pharmaceuticals” Incretin-based drugs for obesity often cause gastrointestinal issues, with tirzepatide having the most reports.
April 2026 in “Science Progress” GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.